State Street
ALDX icon

State Street’s Aldeyra Therapeutics ALDX Stock Holding History

State Street’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9M Buy
1,124,710
+26,110
+2% +$114K ﹤0.01% 3312
2025
Q4 		$5.69M Sell
1,098,600
-4,074
-0.4% -$20.9K ﹤0.01% 2936
2025
Q3 		$5.76M Buy
1,102,674
+46,089
+4% +$240K ﹤0.01% 2944
2025
Q2 		$4.05M Buy
1,056,585
+35,204
+3% +$91K ﹤0.01% 3034
2025
Q1 		$5.87M Sell
1,021,381
-11,992
-1% -$70.9K ﹤0.01% 2812
2024
Q4 		$5.16M Buy
1,033,373
+59,465
+6% +$305K ﹤0.01% 2958
2024
Q3 		$5.25M Buy
973,908
+16,188
+2% +$77K ﹤0.01% 2951
2024
Q2 		$3.17M Buy
957,720
+18,151
+2% +$71.1K ﹤0.01% 3119
2024
Q1 		$3.07M Buy
939,569
+40,560
+5% +$133K ﹤0.01% 3123
2023
Q4 		$3.16M Sell
899,009
-2,166,958
-71% -$6.69M ﹤0.01% 3153
2023
Q3 		$20.5M Buy
3,065,967
+24,101
+0.8% +$179K ﹤0.01% 2167
2023
Q2 		$25.5M Buy
3,041,866
+2,868,585
+1,655% +$28.3M ﹤0.01% 2089
2023
Q1 		$1.72M Hold
173,281
– – ﹤0.01% 3386
2022
Q4 		$1.21M Sell
173,281
-600
-0.3% -$3.43K ﹤0.01% 3519
2022
Q3 		$929K Hold
173,881
– – ﹤0.01% 3611
2022
Q2 		$694K Sell
173,881
-703,916
-80% -$2.42M ﹤0.01% 3718
2022
Q1 		$3.9M Sell
877,797
-2,204,555
-72% -$8.78M ﹤0.01% 3300
2021
Q4 		$12.3M Sell
3,082,352
-345,027
-10% -$2.63M ﹤0.01% 2792
2021
Q3 		$30.1M Buy
3,427,379
+294,240
+9% +$2.7M ﹤0.01% 2180
2021
Q2 		$35.5M Buy
3,133,139
+710,115
+29% +$8.54M ﹤0.01% 2104
2021
Q1 		$28.8M Buy
2,423,024
+2,402,324
+11,605% +$27.7M ﹤0.01% 2128
2020
Q4 		$142K Buy
20,700
+1,600
+8% +$11.2K ﹤0.01% 3787
2020
Q3 		$142K Hold
19,100
– – ﹤0.01% 3687
2020
Q2 		$80K Sell
19,100
-383,909
-95% -$1.4M ﹤0.01% 3672
2020
Q1 		$995K Sell
403,009
-14,198
-3% -$63.9K ﹤0.01% 3308
2019
Q4 		$2.42M Buy
417,207
+18,351
+5% +$106K ﹤0.01% 3186
2019
Q3 		$2.1M Sell
398,856
-352
-0.1% -$1.9K ﹤0.01% 3199
2019
Q2 		$2.4M Buy
399,208
+44,006
+12% +$331K ﹤0.01% 3170
2019
Q1 		$3.21M Buy
355,202
+70,722
+25% +$601K ﹤0.01% 2967
2018
Q4 		$2.36M Buy
284,480
+37,690
+15% +$386K ﹤0.01% 3055
2018
Q3 		$3.41M Buy
246,790
+10,164
+4% +$82.5K ﹤0.01% 3046
2018
Q2 		$1.88M Buy
236,626
+210,695
+813% +$1.68M ﹤0.01% 3291
2018
Q1 		$194K Buy
25,931
+3,262
+14% +$24.8K ﹤0.01% 3560
2017
Q4 		$155K Buy
22,669
+4,169
+23% +$27.5K ﹤0.01% 3585
2017
Q3 		$133K Buy
+18,500
New +$96.6K ﹤0.01% 3624

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street's ALDX Position: Q1 2026 in Review

State Street increased its Aldeyra Therapeutics (ALDX) stake by 2.4% in Q1 2026, buying an estimated $114K and bringing the position to 1,124,710 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3312.

State Street first reported a position in ALDX in Q3 2017 and has held it in 35 quarters since. The position peaked at $35.5M in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • State Street held 1,124,710 shares of Aldeyra Therapeutics worth $1.9M as of Q1 2026.
  • State Street bought 26,110 Aldeyra Therapeutics shares in Q1 2026, an estimated $114K.
  • Aldeyra Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3312 holding.
  • State Street first reported a position in Aldeyra Therapeutics in Q3 2017 and has held it in 35 quarters since.
  • State Street's Aldeyra Therapeutics position peaked at $35.5M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.